Efficacy of different beta-blockers in the treatment of long QT syndrome

Journal of the American College of Cardiology

Volumn 64, Issue 13, 2014, Pages 1352-1358

  Abu Zeitone, Abeer ^a   Peterson, Derick R ^a   Polonsky, Bronislava ^a   McNitt, Scott ^a   Moss, Arthur J ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

atenolol; long QT syndrome; metoprolol; nadolol; propranolol; blocker therapy

Indexed keywords

ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; METOPROLOL; NADOLOL; PROPRANOLOL;

ADOLESCENT; ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE REGISTRY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GENOTYPE; HUMAN; LONG QT SYNDROME; LONG QT SYNDROME 1; LONG QT SYNDROME 2; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRESCRIPTION; RECURRENT DISEASE; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; YOUNG ADULT; CHILD; COMPARATIVE STUDY; FAINTNESS; HEART ARREST; INFANT; MULTIVARIATE ANALYSIS; NEWBORN; PRESCHOOL CHILD; PROPORTIONAL HAZARDS MODEL; REGISTER; REGRESSION ANALYSIS; SUDDEN CARDIAC DEATH; TIME; TREATMENT OUTCOME; Β-BLOCKER THERAPY;

ATENOLOL; LONG QT SYNDROME; METOPROLOL; NADOLOL; PROPRANOLOL; Β-BLOCKER THERAPY;

ADOLESCENT; ADRENERGIC BETA-ANTAGONISTS; ADULT; ATENOLOL; CHILD; CHILD, PRESCHOOL; DEATH, SUDDEN, CARDIAC; FEMALE; GENOTYPE; HEART ARREST; HUMANS; INFANT; INFANT, NEWBORN; LONG QT SYNDROME; MALE; METOPROLOL; MULTIVARIATE ANALYSIS; NADOLOL; PROPORTIONAL HAZARDS MODELS; PROPRANOLOL; REGISTRIES; REGRESSION ANALYSIS; RISK FACTORS; SYNCOPE; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84908299222     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2014.05.068     Document Type: Article

References (23)

1. I. Goldenberg, W. Zareba, and A.J. Moss Long QT syndrome Curr Probl Cardiol 33 2008 629 694
2. D.P. Zipes, A.J. Camm, and M. Borggrefe ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society J Am Coll Cardiol 48 2006 e247 e346
3. R. Antonelli-Incalzi, and C. Pedone Respiratory effects of beta-adrenergic receptor blockers Curr Med Chem 14 2007 1121 1128
4. R.V. Lewis, and C. Lofthouse Adverse reactions with beta-adrenoceptor blocking drugs: an update Drug Saf 9 1993 272 279
5. P. Chockalingam, L. Crotti, and G. Girardengo Not all beta-blockers are equal in the management of long QT syndrome types 1 and 2: higher recurrence of events under metoprolol J Am Coll Cardiol 60 2012 2092 2099
6. A.J. Moss, and J.L. Robinson Long QT syndrome Heart Dis Stroke 1 1992 309 314
7. S.E. Lehnart, M.J. Ackerman, and D.W. Benson Jr. Inherited arrhythmias: a National Heart, Lung, and Blood Institute and Office of Rare Diseases workshop consensus report about the diagnosis, phenotyping, molecular mechanisms, and therapeutic approaches for primary cardiomyopathies of gene mutations affecting ion channel function Circulation 116 2007 2325 2345
8. D. Cox Regression models and life tables (with discussion) J R Stat Soc Series B Stat Methodol 34 1972 187 220
9. A.J. Sauer, A.J. Moss, and S. McNitt Long QT syndrome in adults J Am Coll Cardiol 49 2007 329 337
10. I. Goldenberg, A.J. Moss, and D.R. Peterson Risk factors for aborted cardiac arrest and sudden cardiac death in children with the congenital long-QT syndrome Circulation 117 2008 2184 2191
11. A.J. Moss, W. Zareba, and W.J. Hall Effectiveness and limitations of beta-blocker therapy in congenital long-QT syndrome Circulation 101 2000 616 623
12. R. Chatrath, C.M. Bell, and M.J. Ackerman Beta-blocker therapy failures in symptomatic probands with genotyped long-QT syndrome Pediatr Cardiol 25 2004 459 465
13. E.H. Locati, W. Zareba, and A.J. Moss Age- and sex-related differences in clinical manifestations in patients with congenital long-QT syndrome: findings from the International LQTS Registry Circulation 97 1998 2237 2244
14. P.J. Schwartz, S.G. Priori, and C. Spazzolini Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias Circulation 103 2001 89 95
15. A.A. Wilde, R.J. Jongbloed, and P.A. Doevendans Auditory stimuli as a trigger for arrhythmic events differentiate HERG-related (LQTS2) patients from KVLQT1-related patients (LQTS1) J Am Coll Cardiol 33 1999 327 332
16. S.G. Priori, C. Napolitano, and P.J. Schwartz Association of long QT syndrome loci and cardiac events among patients treated with beta-blockers JAMA 292 2004 1341 1344
17. K. Kawakami, T. Nagatomo, and H. Abe Comparison of HERG channel blocking effects of various beta-blockers: implication for clinical strategy Br J Pharmacol 147 2006 642 652
18. D.W. Wang, A.M. Mistry, and K.M. Kahlig Propranolol blocks cardiac and neuronal voltage-gated sodium channels Front Pharmacol 1 2010 144
19. A. Besana, D.W. Wang, and A.L. George Jr. Nadolol block of Nav1.5 does not explain its efficacy in the long QT syndrome J Cardiovasc Pharmacol 59 2012 249 253
20. P.J. Schwartz, S.G. Priori, and M. Cerrone Left cardiac sympathetic denervation in the management of high-risk patients affected by the long-QT syndrome Circulation 109 2004 1826 1833
21. W. Zareba, A.J. Moss, and J.P. Daubert Implantable cardioverter defibrillator in high-risk long QT syndrome patients J Cardiovasc Electrophysiol 14 2003 337 341
22. I. Goldenberg, J. Bradley, and A. Moss Beta-blocker efficacy in high-risk patients with the congenital long-QT syndrome types 1 and 2: implications for patient management J Cardiovasc Electrophysiol 21 2010 893 901
23. G.M. Vincent, P.J. Schwartz, and I. Denjoy High efficacy of beta-blockers in long-QT syndrome type 1: contribution of noncompliance and QT-prolonging drugs to the occurrence of beta-blocker treatment "failures." Circulation 119 2009 215 221